Now Medtronic has enhanced its Percept™ DBS neurostimulators with exclusive BrainSense™ Adaptive technology†, introducing aDBS for people living with Parkinson's.

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions ...

Now Medtronic has enhanced its Percept™ DBS neurostimulators with exclusive BrainSense™ Adaptive technology, introducing aDBS for people living with Parkinson's.

Medtronic now expects BrainSense aDBS and BrainSense EI to be available in Europe in early 2025. The global neurological devices market was valued at $12.5bn in 2023 and is forecast to reach $20.9 ...

Dr. Helen Bronte-Stewart shows a Medtronic neurostimulator, the device implant that delivers adaptive Deep Brain Stimulation (aDBS) with electrical signals that adapt in response to the Parkinson ...

Medtronic's BrainSense aDBS personalizes Parkinson's therapy in real-time, minimizing manual adjustments for better symptom control. BrainSense Electrode Identifier speeds up initial DBS ...

Earlier this year, Medtronic received approval from European regulators for its adaptive deep brain simulation (aDBS) technology, which includes an implant that can dynamically adjust signals to ...

Medtronic now expects BrainSense aDBS and BrainSense EI to be available in Europe in early 2025. The global neurological devices market was valued at $12.5bn in 2023 and is forecast to reach $20.9 ...

Earlier this year, Medtronic received approval from European regulators for its adaptive deep brain stimulation (aDBS) technology, which includes an implant that can dynamically adjust signals to ...

On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep ...